Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vanessa N Raabe

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Infection Control and Hospital Epidemiology|September 16, 2020
Serosurvey on healthcare personnel caring for patients with Ebola virus disease and Lassa virus in the United StatesColleen S Kraft, Aneesh K Mehta, Jay B Varkey, et al.
Hospital Pediatrics|October 9, 2020
Characteristics of Hospitalized Children With SARS-CoV-2 in the New York City Metropolitan AreaSourabh Verma, Rishi Lumba, Heda M Dapul, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa FeverVanessa N Raabe, Gerrit Kann, Bruce S Ribner, et al.
Journal of the Pediatric Infectious Diseases Society|August 26, 2020
A Pediatric Infectious Diseases Perspective of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Novel Coronavirus Disease 2019 (COVID-19) in ChildrenAndi L Shane, Alice I Sato, Carol Kao, et al.
The Lancet. Microbe|October 7, 2024
Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trialRichard T Davey, Gary L Collins, Nadine Rouphael, et al.
The Lancet. Infectious Diseases|January 29, 2022
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre studySaranya Sridhar, Arnel Joaquin, Matthew I Bonaparte, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Infection Control and Hospital Epidemiology|September 16, 2020
Serosurvey on healthcare personnel caring for patients with Ebola virus disease and Lassa virus in the United StatesColleen S Kraft, Aneesh K Mehta, Jay B Varkey, et al.
Hospital Pediatrics|October 9, 2020
Characteristics of Hospitalized Children With SARS-CoV-2 in the New York City Metropolitan AreaSourabh Verma, Rishi Lumba, Heda M Dapul, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa FeverVanessa N Raabe, Gerrit Kann, Bruce S Ribner, et al.
Journal of the Pediatric Infectious Diseases Society|August 26, 2020
A Pediatric Infectious Diseases Perspective of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Novel Coronavirus Disease 2019 (COVID-19) in ChildrenAndi L Shane, Alice I Sato, Carol Kao, et al.
The Lancet. Microbe|October 7, 2024
Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trialRichard T Davey, Gary L Collins, Nadine Rouphael, et al.
The Lancet. Infectious Diseases|January 29, 2022
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre studySaranya Sridhar, Arnel Joaquin, Matthew I Bonaparte, et al.
Pageof 2